Salix reports encouraging results from Phase III encephalopathy study
This study demonstrates that the protocol-specified, intent-to-treat, primary endpoint comparison of a six-month course of rifaximin at 550mg dosed twice-a-day provides a highly statistically significant result in preventing
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.